Invest in

Drug-Patent Cliffs

15.6%
4.0%
1.5%

Expiring Patents, Aspiring Generics

Big Pharma is headed for a big change. And generics are getting ready to grab their share. Branded drugs with sales of $86 billion would lose patent protection during 2013 to 2017.[1] Some of the most lucrative targets for generics in 2013 include Eli Lilly’s Cymbalta, Biogen Idec’s Avonex and Merck KGaA's Rebif. These drugs generated global sales worth $10 billion in 2012.[2] Generic drugs, once available, are typically 30% to 80% cheaper than the brand names, and can capture 80% of the market within the first year.[3] Which means the next few years hold an unprecedented growth opportunity for the generic drug industry. And that has investors feeling feverish. See more
15.6%
4.0%
1.5%
Invest in Thematic Portfolios
Create your own customizable basket of up to 30 stocks or ETFs for just $9.95.
Motif Index 1 YR Return
Drug-Patent Cliffs Benchmark
With this Motif, you can buy the following basket of stocks for just $9.95:
Weight Segment & Stocks Symbol 1 MO / 1 YR Return
100% Generic Drugs 10.5%
18.2% Dr. Reddy's Laboratories Ltd RDY 23.8%
18.0% Taro Pharmaceutical Industries Ltd. TARO 2.7%
14.2% Mylan N.V. MYL 3.8%
11.6% Sagent Pharmaceuticals Inc. SGNT 9.6%
8.1% Impax Laboratories Inc. IPXL 42.4%
7.7% Akorn Inc. AKRX 25.1%
5.7% Abbott Laboratories ABT 3.6%
5.0% Mallinckrodt plc MNK 0.6%
4.6% Lannett Co Inc LCI 31.9%
2.3% Sanofi American Depositary Shares (Each repstg one-half of one) SNY 13.8%
1.7% Teva Pharmaceutical Industries Limited American Depositary Share TEVA 15.0%
1.2% The Medicines Company MDCO 30.9%
1.1% Cambrex Corporation CBM 6.3%
0.5% Endo International PLC ENDP 68.8%

Quotes delayed 15 mins. Currently Aug 24, 2016 8:51:14 PM. Fields are marked with -- when data is unavailable.